Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 803 results for "eisai"

Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at...
Freshnews.com

FDA to Review Fycompa for Monotherapy Use in Partial-Onset Sei...

The label change would include use as a monotherapy for partial-onset seizures Eisai announced the submission of a supplemental application for a proposed label change for Fycompa (perampanel) which would include use as monotherapy for the ... Monthly Prescribing Reference, 35 minutes ago
[x]  

102 images for eisai

Minyanville, 1 week ago
Freshnews.com, 6 days ago
Pharmafile, 1 week ago
BioPharma Dive, 1 week ago
Scrip Intelligence, 1 week ago
Scrip Intelligence, 1 week ago
Scrip Intelligence, 1 week ago
Pharmafile, 2 weeks ago
APN News, 1 week ago
APN News, 1 week ago
pharmaphorum

Eisai cannot understand German agency's recommendation to reject Halaven

Eisai has issued a statement to declare their bewilderment following a decision from the German Institute for Quality and Efficiency in Health Care (IQWiG), the equivalent of NICE in the UK, not to recommend Halaven (eribulin) versus established ...
 Pharmafile3 weeks ago Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven┬« (eribulin) in the Treatment of Advanced Liposarcoma  Yahoo! Finance3 weeks ago EISAI : bewildered as IQWIG fails to recognise OS benefit of liposarcoma drug  4 Traders3 weeks ago German pricing rules hit Eisai's Halaven  pharmaphorum3 weeks ago
[x]  

Eisai's anticancer agent approved for additional indication of CLL in Japan

Eisai's anticancer agent treakisym for injection 100mg has received approval for an additional indication of chronic lymphocytic leukaemia (CLL) in Japan. CLL is a blood cancer that is characterised by neoplastic transformation and excess ...
 CPhI.cn4 weeks ago

BRIEF-Arena Pharmaceuticals, Eisai receive paragraph IV certification

Aug 25 Arena Pharmaceuticals Inc : * Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq * Notification is currently under investigation * Co and Eisai have 45 days from receipt ...
 Reuters UK1 month ago Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'  Reuters UK1 month ago
Freshnews.com

New #ThisIsMBC Campaign Seeks to Raise Awareness of Metastatic Breast Cancer by Encouraging People with This Rarely Discussed, Deadly Stage of the Disease to Share Their Experiences

METAvivor and Eisai Inc. Partner to Urge MBC Community to Discuss Living with Their Diagnosis, How They Draw Strength and Encouragement from Their Support Networks ANNAPOLIS, Md. and WOODCLIFF LAKE, N.J., Sept. 22, 2016 /PRNewswire/ -- "The cancer ...
 PR Newswire5 days ago The cancer has spread and MBC will kill you!  Can India News4 days ago
[x]  
Sys-Con India

Myths and Truths About Thyroid Cancer Educational Initiative Honors Thyroid Cancer Awareness Month with Launch of New #TruthAboutTC Social Media Challenge

The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors' Association, and Eisai Team Up to Increase Awareness by Urging People with Thyroid Cancer to Share their Experiences WOODCLIFF LAKE, N.J., Sept. 21, 2016 /PRNewswire/ -- A thyroid ...
 PR Newswire6 days ago
[x]  

Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies

EXTON, Pa. , Sept. 13, 2016 /PRNewswire/ -- Morphotek ® , Inc., a subsidiary of Eisai Inc., announced today that it entered into a Sponsored Research Agreement (SRA) with Fox Chase Cancer Center (FCCC) to expand its research efforts into the ...
 Minyanville2 weeks ago
[x]  

Vanguard Adds to Eisai Stake

 Guru Focus1 month ago

GLOBAL MAGNESIUM ASCORBYL PHOSPHATEINDUSTRY MARKET 2016 : Eisai, Roche, Mitsui Chemicals, Xiaogan Shenyuan ChemPharm

Global Magnesium Ascorbyl PhosphateIndustry Market includes market Share, Trends, Research, Review, Analysis, Demand, Growth, Supply Chain, Revenue, Growth Rate, Gross Margin, Size, Key Manufacturers Analysis and Forecast.Sarasota, FL -- (SBWIRE) -- ...
 4 Traders3 weeks ago Natural Source Vitamin E Market (Product - Tocopherols, Tocotrienols; Application - Dietary Supplements, Food and Beverages, Cosmetics) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024  Global Information Inc1 week ago Natural Source Vitamin E Market Forecast to 2016-2024 including Market Size, Growth, Major Segments and Leading players  MyNewsDesk6 days ago Natural Source Vitamin E Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024  PR Newswire6 days ago
[x]  

In-Depth Market Analysis On Eisai Co., Ltd. - Product Pipeline Review - 2016

Eisai Co., Ltd. - Product Pipeline Review - 2016is a new market research publication announced by Reportstack. This reportprovides an overview of the Eisai Co., Ltd.'s pharmaceutical research and development focus. The report provides ...
 MyNewsDesk1 week ago Eisai Co., Ltd. - Product Pipeline Review - 2016  Global Information Inc1 week ago Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets  Pharmacy Choice3 weeks ago Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review  MarketResearch.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less